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RESUMO 
INTRODUÇÃO: Os doentes infetados pelo vírus da imunodeficiência adquirida (VIH) em terapêutica 
antirretrovírica combinada (TARC) podem ter distúrbios metabólicos, lipodistrofia e disfunção tiroideia. 
Tem sido investigado o impacto potencial de alterações minor da função tiroideia na composição 
corporal em doente eutiroideus não infetados pelo VIH, mas não na população infetada pelo VIH. Os 
objetivos deste estudo foram comparar os níveis de TSH, T3L e T4L nos doentes eutiroideus com e sem 
lipodistrofia [definida pela clínica e pela razão massa gorda (RMG)] e em quatro grupos de composição 
corporal; e avaliar a possível relação entre a TSH, T3L e T4L e parâmetros demográficos, 
antropométricos, infeciosos e metabólicos. 
MÉTODOS: Estudo transversal incluindo 352 adultos caucasianos não institucionalizados infetados 
pelo VIH-1 sob TARC. Foram avaliados dados demográficos, caracterização da infeção VIH, função 
tiroideia, características antropométricas, composição corporal por DXA e parâmetros metabólicos. 
RESULTADOS: Não houve diferenças significativas entre a mediana de TSH, T3L e T4L de acordo 
com a presença de lipodistrofia (definida pela clínica e pela RMG) e os quatro grupos de composição 
corporal. A TSH estava positivamente correlacionada com a idade e negativamente com a contagem de 
células CD4. Na análise multivariada, depois de ajustar para a idade, género e índice de massa corporal 
(IMC), a TSH permaneceu positivamente associada com a idade e negativamente com a contagem de 
células CD4. A T3L estava positivamente correlacionada com a duração da infeção por VIH e 
negativamente com a idade, pressão arterial sistólica (PAS) e pressão arterial diastólica (PAD). Na 
análise multivariada, não houve associações significativas com a T3L. A T4L estava positivamente 
correlacionada com a duração da infeção e negativamente com a PAD, colesterol total e C-LDL. Na 
análise univariada, a FT4 estava negativamente associada com o IMC, colesterol total e C-LDL, mas no 
modelo de regressão linear múltiplo apenas a associação com o LDL-C permaneceu significativa. 
CONCLUSÕES: Não houve diferenças nos valores de TSH, T3L e T4L de acordo com a composição 
corporal em doentes eutiroideus infetados pelo VIH. Os níveis de TSH estavam associados 
positivamente com a idade e negativamente com a contagem de células CD4, mesmo na análise 
multivariada. Os doentes eutiroideus podem ter anomalias lipídicas e pressão sanguínea elevada. 
PALAVRAS-CHAVE: VIH, terapêutica antirretrovírica, tiroide, lipodistrofia, composição corporal, 
razão massa gorda, pressão sanguínea, dislipidemia.  
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ABSTRACT 
BACKGROUND: Human immunodeficiency virus (HIV)-infected patients on combined antiretroviral 
therapy (cART) may have metabolic disorders, lipodystrophy and thyroid dysfunction. It has been 
investigated the potential impact of minor changes in thyroid function on body composition of euthyroid 
HIV non-infected patients, but not in HIV-infected population. The aims of this study were to compare 
TSH, FT3 and FT4 levels in euthyroid patients with and without lipodystrophy [defined by clinical and 
by fat mass ratio (FMR)] and in four groups of body composition; and to assess the possible relationship 
between TSH, FT3 and FT4 and demographics, anthropometrics, infectious and metabolic parameters. 
METHODS: Cross-sectional study including 352 HIV-1-infected non-institutionalized Caucasian adults 
on cART. Demographic data, HIV infection characterization, thyroid function, anthropometric features, 
body composition by DXA and metabolic parameters were evaluated. 
RESULTS: There were no significant differences between the median of TSH, FT3 and FT4 according 
to the presence of lipodystrophy (defined by clinical and by FMR) and the four groups of body fat 
composition. TSH was positively correlated with age and negatively with CD4 cell count. In 
multivariate analysis, after adjustment for age, gender and body mass index (BMI), TSH remained 
positively associated with age and negatively associated with CD4 cell count. FT3 was positively 
correlated with duration of HIV infection and negatively with age, systolic blood pressure (SBP) and 
diastolic blood pressure (DBP). In multivariate analysis, there were no significant associations with FT3. 
FT4 was positively correlated with duration of infection and negatively with DBP, total cholesterol and 
LDL-C. In univariate analysis, FT4 was negatively associated with BMI, total cholesterol and LDL-C, 
however in the multiple linear regression model (with age, gender and BMI as covariates) only the 
association with LDL-C remained significant. 
CONCLUSIONS: There were no differences in TSH, FT4 and FT3 values according to body 
composition in euthyroid HIV-infected patients. TSH levels were positively associated with age and 
negatively with CD4 cell count, even in multivariate analysis. Euthyroid patients can have lipid 
abnormalities and raised blood pressure. 
KEYWORDS: HIV, antiretroviral therapy, thyroid, lipodystrophy, body composition, fat mass ratio, 
blood pressure, dyslipidemia.  
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BACKGROUND 
 
 The acquired immune deficiency syndrome (AIDS), primarily reported in 1981, became a 
leading cause of mortality worldwide [1]. With the successful introduction of combined antiretroviral 
therapy (cART) in 1996, human immunodeficiency virus (HIV)-related morbidity and mortality have 
declined substantially [1, 2]. However, and due to an increased survival, there are more and more people 
living with this infection. At the end of 2010 it was estimated that nearly 34 million adults and children 
were living with HIV infection worldwide [2]. 
 The use of cART has been associated with many side effects, including lipodystrophy, 
dyslipidemia, insulin resistance, increased blood pressure, decreased bone mineral density and 
dysfunction of the adrenal, gonadal and thyroidal axes [3-5]. Önen suggested that these comorbidities 
are not part of the “normal” aging process [4]. However, the mechanisms responsible for cART-related 
metabolic disorders are not fully understood and there is a growing recognition that inflammatory 
cytokines and HIV infection by itself can be the etiologic agents of these metabolic abnormalities [5, 6]. 
Lipodystrophy is characterized by selective loss of adipose tissue from particular anatomical 
regions and can be localized or generalized [7]. Acquired lipodystrophies occur more frequently than the 
inherited types and the most prevalent subtype in the clinic is acquired partial lipodystrophy related to 
cART in HIV-infected patients [7, 8]. With the beginning of molecular genetic era, congenital and 
familial types were associated with mutant gene products and not only characterized by clinical features. 
However, the mechanisms responsible for the relationship between HIV and lipodystrophy remain 
partially unknown [7]. HIV-associated lipodystrophy syndrome is characterized by loss of subcutaneous 
fat (lipoatrophy) from the face and limbs with or without deposition of excess fat (lipohypertrophy) in 
the neck and upper back (causing a double chin and a buffalo hump), abdomen and trunk, resulting in 
peripheral fat wasting and central adiposity [7-9]. Some patients have peripheral lipoatrophy, others 
have isolated abdominal prominence and a substantial portion has mixed forms including both 
phenotypes [9]. HIV-associated lipodystrophy has been linked to components of metabolic syndrome 
(MS), such as high blood pressure, dyslipidemia and insulin resistance, leading to an increased 
cardiovascular disease risk [3, 7]. The relationship between cART and fat redistribution is associated 
with prolonged duration of treatment and is highly linked to the use of protease inhibitors (PI) drugs, 
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although it has been also related to other antiretroviral drugs [3, 8, 9]. In his clinical review, Chen 
reported that prevalence of lipodystrophy among HIV-infected patients was highly variable according to 
different authors, ranging between 8% and 84% (due to different definition and diagnosis criteria). He 
noticed that near 40% of patients treated with PI developed lipodystrophy [8]. 
Thyroid hormones regulate the metabolism and function of many tissues, such as liver, heart, 
skin, muscle and adipose tissue. They are involved via thyroid hormone receptors (TRs) in adipogenesis 
and adipose tissue lipogenesis and lipolysis [10, 11]. All the isoforms of TRs (both TRA1 and TRB1) 
are expressed in white adipose tissue [12]. Moreover, the monocarboxylate transporter 8 (MCT8) is a 
thyroid-hormone-specific transporter that is ubiquitously expressed, including in human subcutaneous 
adipose tissue (SAT) [12]. Overt hypothyroidism is clearly associated with body weight excess and 
obesity, but the potential impact of minor changes in thyroid function on anthropometric measures of 
euthyroid HIV non-infected patients remains under investigation [13-16]. So far there are still no studies 
exploring this relationship among HIV-infected patients. 
Due to the important role of TH on adipocyte metabolism and as HIV-associated lipodystrophy 
results from changes in adipose tissue, we hypothesized that minor changes in thyrotropin (TSH), free 
3,5,3’-triiodothyronine (FT3) and free thyroxine (FT4) may have a significant role in the peculiar body 
fat redistribution of these patients. 
The aims of the current study were (1) to compare the levels of TSH, FT3 and FT4 in euthyroid 
patients with and without lipodystrophy [(defined by clinical and by fat mass ratio (FMR)] and in four 
different groups of body composition (no lipodystrophy; isolated central fat accumulation; isolated 
lipoatrophy; and mixed forms of lipodystrophy); (2) and to assess the possible relationship between 
TSH, FT3 and FT4 and demographic, anthropometric, infectious and metabolic parameters.  
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METHODS 
 
Subjects and study design 
As part of a cross-sectional study, 352 clinically stable HIV-infected non-institutionalized 
Caucasian adults (234 men and 118 women) receiving antiretroviral therapy, consecutively referred 
from the Infectious Diseases Outpatient Clinic were evaluated. Only patients on cART were included, 
because lipodystrophy is related with this therapy [8]. Patients without thyroid function test results and 
with thyroid dysfunction (such as overt and subclinical hypothyroidism, overt and subclinical 
hyperthyroidism, Graves’ disease, Hashimoto thyroiditis, papillary thyroid carcinoma, toxic 
multinodular goiter, isolated low FT4 level and nonthyroidal illness syndrome) were excluded. The 
study protocol was approved by the Hospital Ethics Committee and each patient provided informed 
consent. 
 
Clinical assessments 
For each patient the following information was collected using a standardized protocol: 
demographic data (age, gender, smoking status), history of hypertension, diabetes and use of 
antihypertensive, antidiabetic and lipid-lowering drugs, duration of HIV infection, HIV infection risk 
factors, duration of cART and characterization of the infection. The “Centers for Disease Control and 
Prevention” (CDC) criteria for staging of HIV infection were used [17]. The HIV infection risk factors 
were classified into four different groups: intravenous drug use; homosexual and bisexual contact; 
heterosexual contact; and other (hemophiliacs, transfused patients and unknown risk). Antiretroviral 
treatment analysis included only the last therapy used up to collecting data, the type of drugs used and 
the total duration of cART since infection diagnoses. 
Weight, height, resting blood pressure, circumferences of neck, waist, hip, thigh and arm were 
measured, as previously described [18, 19]. The subjects were standing upright, with the face directed 
forwards, arms by the sides and gluteal muscles and shoulders relaxed. All measurements were taken by 
the same well-experienced physician with standard techniques [20]. Body weight was measured using a 
TANITA scale (Tanita®, model TBF 300), with patients wearing light clothes without shoes. Height was 
measured to the nearest centimetre in the standing position using a wall stadiometer (Holtain Limited 
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Crymych, Dyfed®). Body mass index (BMI) was calculated as weight in kilograms divided by the 
squared height in metres. Resting blood pressure was measured on a single occasion using a standard 
mercury sphygmomanometer with the cuff on the left upper arm. 
Clinical lipodystrophy (CL) was defined as a peripheral lipoatrophy with or without a central fat 
accumulation assessed by both patient and practitioner [21]. Patients were classified as without CL when 
none of the previously described features were present. Presence of central fat accumulation or 
abdominal prominence was defined by the measurement of waist circumference using the International 
Diabetes Federation (IDF) criteria for MS, which recommends that the threshold for abdominal obesity 
must be ≥ 94 centimetres in men and ≥ 80 centimetres in women [22]. The clinical assessment was 
performed by the same practitioner. As previously described [21], the patients were placed into four 
different categories according to the presence or absence of either lipoatrophy or abdominal prominence: 
1) No lipodystrophy – patients without clinical lipoatrophy and without abdominal prominence; 2) 
Isolated central fat accumulation – patients without clinical lipoatrophy and with abdominal prominence; 
3) Isolated lipoatrophy – patients with clinical lipoatrophy and without abdominal prominence; 4) Mixed 
forms of lipodystrophy – patients with clinical lipoatrophy and with abdominal prominence. 
Body composition was assessed with whole-body dual-energy X-ray absorptiometry (DXA – 
Lunar Expert XL). DXA measurement was performed while the patient was in a supine position, with 
standard positioning of the arms and feet. Markers used in this study for trunk and lower limbs that 
defined regions of interest were those indicated by the manufacturer. Regional fat mass values were 
grouped and analyzed for the following anatomical regions: arms, legs, trunk and total body. The FMR 
was calculated as the ratio between the percentage of the trunk fat mass and the percentage of the lower 
limbs fat mass (FMR = % of the trunk fat mass/ % of the lower limb fat mass) [23, 24]. 
 
Laboratory analysis 
A venous blood sample was drawn after a 12-hour overnight fast. All the samples were analyzed 
at the central laboratory of our hospital. Plasma glucose, total cholesterol, low density lipoprotein 
cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) were 
determined using automatic standard routine enzymatic methods [18]. CD4 cell count was determined 
by flow cytometry and plasma HIV-1 RNA loads were measured by a quantitative reverse transcriptase 
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polymerase chain reaction, with a lower limit of detection of 50 copies/mL. Leptin (human leptin RIA, 
kit, Linco Research) and adiponectin (human adiponectin RIA, kit, Linco Research) were performed in 
Nobre Laboratory of the Porto Medical School. The intra-assay and inter-assay precision was 4.6% and 
5.0%, respectively, for leptin; the intra-assay and inter-assay precision was 1.78% and 9.25%, 
respectively, for adiponectin. The MS was defined using the most recent criteria for its clinical 
diagnosis, proposed by several major organizations (including IDF) in 2009 [22]. 
TSH, FT3 and FT4 serum levels were measured by a chemiluminescence method (Abbott kit). 
The normal serum levels for TSH, FT4 and FT3 were defined according with the reference values of the 
central laboratory of our hospital. The normal range levels were 0.350 to 5.500 mUI/mL for TSH, 0.89 
to 1.80 ng/dL for FT4 and 2.3 to 4.2 pg/mL for FT3. Euthyroidism was defined as normal TSH, T3L and 
FT4 values. The diagnosis of thyroid disease was made from laboratory parameters, clinic database and 
thyroid medication use. 
 
Statistical analysis 
Data were described as mean and standard deviation (SD) for quantitative variables or as median 
and respective interquartile range (IQR) and compared using the Student-t test or the Mann-Whitney 
test, respectively. For the comparison between the four groups of fat distribution and the thyroid 
function parameters the Kruskall-Wallis test was used. Categorical variables were described as counts 
and proportions, and compared using the chi-square or Fisher’s exact test. 
For estimating the association between thyroid function parameters (TSH, FT3, FT4) levels and 
anthropometric, metabolic and body composition characteristics, Spearman correlation coefficients were 
calculated.  
As the dependent variables (TSH, FT3, FT4) had distributions different than the normal, they 
were log transformed. Using the log transformed dependent variables; multivariate linear regression 
models were computed to estimate the independent association between thyroid function parameters and 
metabolic and clinical characteristics.  
Statistical analysis was performed using the SPSS version 19.0 software (SPSS Inc., Chicago, 
Illinois, USA). All probabilities were two tailed and p values <0.05 were regarded as significant.  
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RESULTS 
 
 This study included 352 (234 men and 118 women) euthyroid HIV-infected patients on cART. 
Table 1 shows the demographic, anthropometric, infectious and cardiovascular risk factors of the sample 
according to the four groups of body fat distribution. Men had more frequently isolated lipoatrophy or 
absence of lipodystrophy while women had isolated central fat accumulation and mixed forms of 
lipodystrophy. Mixed forms were more prevalent in older patients. Regarding smoking status, current 
smokers were more frequently classified as with no lipodystrophy and with isolated lipoatrophy, while 
isolated central adiposity and mixed forms were more frequent in those patients that never smoked. 
Regarding anthropometric parameters, as expected patients with abdominal prominence (both 
isolated and mixed forms) had a higher mean of BMI, neck, waist, hip, thigh and arm circumferences 
and waist/hip ratio. On the other hand, FMR mean was higher in patients with isolated lipoatrophy or 
mixed forms. The prevalence of isolated lipoatrophy and mixed forms of lipodystrophy were higher in 
patients with longer duration of HIV infection and cART. As far as HIV risk factors are concerned, 
patients with isolated lipoatrophy were more frequently intravenous drug users while those into other 
body composition group had usually heterosexual risk. The prevalence of PI therapy was higher in 
patients without lipodystrophy or with isolated central fat accumulation. No statistically significant 
differences were found between the four groups of body composition and viral suppression, CD4 cell 
count, CDC stage and use of nucleoside reverse transcriptase inhibitors (NRTI) and non-nucleoside 
reverse transcriptase inhibitors (NNRTI). 
Considering metabolic parameters and cardiovascular risk factors, SBP was lower in patients 
with isolated lipoatrophy, serum glucose was higher when mixed forms were present, total cholesterol 
and LDL-C levels were significantly higher in patients with isolated central fat accumulation and mixed 
forms. No differences were observed regarding to DBP, HDL-C and TG. Leptin mean levels were 
higher in patients with central fat accumulation and mixed forms, while the adiponectin levels were 
significantly higher in patients without lipodystrophy. 
Regarding thyroid function, there were no statistically significant differences between the 
median of TSH, FT3 and FT4 according to the presence of lipodystrophy defined clinically or by the 
FMR (Table 2) and the four groups of body fat composition (Table 3).  Also, the median of TSH, FT3 
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and FT4 did not differ significantly according to MS features (Table 4), BMI categories and presence or 
absence of hypertension (data not shown). 
TSH levels were positively correlated with age (r = 0.134; p = 0.013) and negatively correlated 
with CD4 cell count (r = -0.138; p = 0.010) (data not shown). In multivariate analysis, after adjustment 
for age, gender and BMI, TSH levels remained positively associated with age (β = 0.007; p = 0.005) and 
negatively associated with CD4 cell count (β = -0.107; p = 0.006) (Table 5). 
FT3 levels were positively correlated with duration of HIV infection (r = 0.109; p = 0.048) and 
negatively with age (r = -0.121; p = 0.027), SBP (r = -0.162; p = 0.003) and DBP (r = -0.119; p = 0.031) 
(data not shown). On the other hand, although FT3 levels were negatively associated with gender in 
univariate analysis (β = -0.002; p = 0.001), after adjustment no significant associations remained (Table 
6). 
FT4 levels were positively correlated with duration of HIV infection (r = 0.109; p = 0.046) and 
negatively with DBP (r = -0.121; p = 0.026), total cholesterol (r = -0.142; p = 0.009) and LDL-C           
(r = -0.177; p = 0.001) (data not shown). In univariate analysis, FT4 levels were negatively associated 
BMI (β = -0.008; p = 0.035), total cholesterol (β = -0.001; p = 0.018) and LDL-C levels (β = -0.001;       
p = 0.002) and tended to be positively associated with duration of HIV infection (β = 0.052; p = 0.059). 
However in the multiple linear regression model (with age, gender and BMI as covariates) only the 
association between FT4 and LDL-C remained statistically significant (β = -0.001; p = 0.006) (Table 7).  
Interestingly, there was no correlation between TSH, FT3 and FT4 levels (data not shown). 
Also, there were no statistically significant correlations between TSH, FT3 and FT4 and BMI, cART 
duration, waist, hip and thigh circumferences, waist/hip ratio, glucose, HDL-C, TG, leptin, adiponectin 
and fat mass (free, total, upper limbs, lower limbs and trunk) (data not shown). 
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DISCUSSION 
 
Among HIV-infected patients, some studies have reported that overt thyroid dysfunction occurs 
between 1% and 2% and subclinical abnormalities may be presented in nearly 35% (often subclinical 
hypothyroidism) [6, 25, 26]. 
Studies on the relationship of thyroid function and lipodystrophy are scarce [6, 27, 28]. Some 
authors described that lipodystrophy wasn’t associated with thyroid function abnormalities [6, 27].  
Indeed, to knowledge of the authors, this was the first study carried out in HIV-infected patients that 
investigated the possible relationship between changes of thyroid function at the normal range and 
lipodystrophy. In our study, there weren’t statistically significant differences in TSH, FT3 and FT4 
levels between patients with and without lipodystrophy (defined by clinical and by FMR) and in four 
different groups of body composition. Furthermore, no statistically significant correlation was found 
between thyroid measurements and anthropometric (BMI, waist, hip and thigh circumferences and 
waist/hip ratio) or body composition parameters (free, total, upper limbs, lower limbs and trunk fat 
mass). 
Studying lipodystrophy remains difficult because there is a lack of well-defined diagnostic 
criteria, differences among sample populations and a poor knowledge of all the underlying pathogenic 
mechanisms [8]. Despite our results, particular observations reported on literature support the hypothesis 
that changes of thyroid function may be associated with HIV-related lipodystrophy and that this 
relationship may not be observed by serum thyroid hormone measurements but only in target cell or at 
the molecular level (probably with differences between lipoatrophic and lipohypertrophic areas). First, 
HIV infection itself has been associated with higher resting energy expenditure (REE) and cART with 
decreased REE [29, 30]. Sutinen showed that lipodystrophy by itself was associated with increased 
REE, since REE was significantly higher in HIV-patients on cART with lipodystrophy compared with 
those without lipodystrophy, even when adjusted for body weight and fat free mass [31]. Lipodystrophic 
patients had a higher caloric intake, which can be regulated by thyroid hormones [31]. It was described a 
negative correlation between REE and TSH levels and an association of minor changes in thyroid 
function with significant changes in REE [32]. So hypermetabolic state in lipodystrophy may be due to 
thyroid overactivity or in the upper-normal limit. Finally, a recent study involved patients with familial 
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partial lipodystrophy (Dunnigan variety) reported that thigh SAT from lipodystrophic patients had lower 
MCT8 and higher type 2 iodothyronine deiodinase (DIO2) mRNA expression than thigh and abdominal 
SAT from controls. Then, it was suggested that changes in local thyroid hormones availability occur in 
lipoatrophic areas [28]. 
Interestingly in our sample there was no statistically significant correlation between TSH and 
thyroid hormone levels (both FT3 and FT4). The individual changes on feedback mechanism of 
pituitary-thyroid axis and the pulsatile TSH secretion pattern can explain this finding [33]. Furthermore, 
it was suggested that genetic changes can affect the thyrotrophs sensitivity to the feedback regulation by 
thyroid hormones [34]. Therefore, FT4 and especially FT3 (the active cellular form of thyroid hormone) 
values may better reflect the physiological actions of thyroid function in different tissues. 
TSH levels were positively correlated with age, while FT3 levels were negatively correlated 
with age. In multivariate analysis, there was a statistically significant positive association between TSH 
and age, regardless the gender and BMI. In previous studies involving both HIV-infected and uninfected 
populations, the results are controversial. Different authors had reported an inverse association between 
age and TSH [35], a positive association in both genders [14, 36] and also a positive correlation between 
TSH and age only in women [33]. 
In our euthyroid sample, it was found a statistically significant negative correlation between 
TSH (but not thyroid hormones) and CD4 cell count. Also in multivariate analysis, after adjustment for 
age, gender and BMI, TSH levels remained negatively associated with CD4 cell count. This relationship 
with immune system was also described by other authors in HIV-infected population. Madeddu 
observed a negative correlation between TSH and CD4 cells nadir in HIV-infected patients on cART 
[26]. On the other hand, Collazos found a positive correlation between FT4 and CD4 cell count [37] and 
Beltran showed that low CD4 cell count was a risk factor for hypothyroidism [6]. This relationship is 
likely to be mediated by proinflammatory cytokines as tumor necrosis factor alpha (TNF-α), which has 
been found increased in HIV patients both before and during therapy and has receptors in thyroid 
follicular cells [26, 38]. In our study, FT3 and FT4 levels had a statistically significant positive 
correlation with the duration of HIV infection. However, in univariate and multivariate analysis, there 
was a lack of association between there parameters. There were no associations of thyroid function 
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regarding to the cART duration, which is not concordant with the positive correlation between TSH 
value and therapy duration described by Madeddu [26]. 
The influence of thyroid function on blood pressure homeostasis has been evaluated during the 
last years. Both overt and subclinical hypothyroidism are often associated with arterial hypertension 
(from 10 to 25% has diastolic hypertension), due to an increased systemic vascular resistance, increased 
arterial stiffness and changes in sodium homeostasis [39-41]. On the other hand, hyperthyroidism is a 
secondary cause of isolated systolic hypertension because FT3 reduces peripheral vascular resistance, 
increases heart rate and consequently raises cardiac output, leading to a widened pulse pressure [39, 40]. 
Even in euthyroid patients, thyroid function has been associated with blood pressure homeostasis [41-
45], but unlike this sample previous studies only included HIV non-infected patients. 
In our sample, TSH, FT3 and FT4 levels didn’t differ significantly according to the presence of 
hypertension (only 38.2% had hypertension), but FT3 levels tended to be lower among hypertensive 
patients [p = 0.051 (data not shown)]. Some authors showed that euthyroid hypertensive patients had 
higher TSH levels [41-43]. Gumieniak reported that lower FT4 index (an estimative for FT4 values, 
resulting from the product of T4 total by the thyroid hormone binding ratio) and higher TSH levels 
within the normal range were linked to hypertension, independently of age, gender, BMI, race, smoking 
status and insulin sensibility. In his study, the lower FT4 index was an independent predictor of blood 
pressure salt-sensitivity, one of the key elements in the pathogenesis of hypertension [41]. 
In our study, it was only able to establish statistically significant correlations between thyroid 
hormones (but not TSH) and blood pressure. Serum FT3 was negatively correlated with both SBP and 
DBP and serum FT4 was negatively correlated only with DBP. It has been showed that FT3 and FT4 are 
direct vasodilator agents that promote relaxation of vascular smooth-muscle cells and of skeletal muscle 
resistance arterioles, with consequent decrease of systemic vascular resistance [40, 46], which justifies 
these results. However, in multiple linear regression model (with age, gender and BMI as covariates) 
there were no associations between FT3, FT4 and blood pressure. It was an expected result because age 
and BMI are positively associated with blood pressure [43]. 
Some studies have showed a positive association between TSH within the reference range and 
SBP and DBP, considering both hypertensive and normotensive subjects [42-44]. Iqbal observed a linear 
rise in DBP and also in SBP (but only in females) with the increase of normal range TSH quartile, 
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independently of age, BMI and smoking status [43]. In a cross-sectional study, Saltiki reported a 
positive correlation between TSH and DPB (not SBP), but not in multivariate analysis [44]. On the other 
hand, controversial studies didn’t show relationship between blood pressure and thyroid function at the 
normal range [47, 48]. Gumieniak observed an excessive aggregation of high-normal TSH values in 
hypertensive families and a higher serum TSH levels in healthy subjects with family history of 
hypertension compared with those with negative family history. He suggested the existence of genetic 
variants affecting both blood pressure regulation and TSH levels [45]. 
 Looking for BMI, patients with isolated central fat accumulation and with mixed forms of 
lipodystrophy had a significant higher mean of BMI. As expected, leptin mean levels were higher in 
patients with central fat accumulation and mixed forms, since leptin concentration is proportional to 
adipocyte mass [49]. In our sample, thyroid function into normal range didn’t differ according to BMI 
and there was no significant correlation between these two parameters. It was only observed a negative 
association between BMI and FT4 in univariate (but not multivariate) analysis. In euthyroid HIV non-
infected patients, previous studies found an association between BMI and changes in thyroid function, 
but this relationship could differ between lower grades of overweight and morbid obesity. Asvold e 
Nyrnes reported a positive association between BMI and TSH among men and women [13, 14], while 
Makepeace showed a significant inverse relationship between FT4 concentration and BMI in euthyroid 
subjects [15]. Michalaki showed that euthyroid morbidity obese subjects have raised T3, FT3, T4 and 
TSH levels compared with those not overweight [16]. This relationship seems to be changed by smoking 
status, but it is still controversial [13-15]. Indeed, some studies didn’t found any association between 
thyroid function and BMI [34, 50]. The relationship between obesity and lipodystrophy in HIV-infected 
patients was already studied previously [19]. 
In our population, FT4 levels were negatively correlated with total cholesterol and LDL-C. In 
univariate analysis there was also found a positive association between FT4 levels and total cholesterol 
and LDL-C. However in the multiple linear regression model (with age, gender and BMI as covariates) 
only the association between FT4 and LDL-C remained statistically significant. There was no 
association between thyroid function and HDL-C and TG. Overt and subclinical hypothyroidism is 
associated with dyslipidemia [39]. According to previous studies including HIV non-infected patients, 
TSH within the reference range were positively associated with total cholesterol and LDL-C and 
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negatively with HDL-C [51]. Indeed, a large population-based study including 30000 subjects found that 
TSH levels were positively correlated with total cholesterol, LDL-C and TG and negatively correlated 
with HDL-C [52]. This association could be modified by the age, insulin sensitivity, smoking status and 
time since the last meal [51, 52].  
As mentioned previously, this was the first study performed on HIV-infected patients to 
investigate the association between lipodystrophy and thyroid function at the normal range. One of the 
strengths of our study was the absence of inter-observer variability because all measurements were taken 
by the same practitioner. Also there was a careful adjustment for the main confounding factors as age, 
gender and BMI. However the present study has some limitations. There is a possible selection bias 
since all patients included were referred by the Infectious Disease specialist specifically for 
lipodystrophy or metabolic disorders related to cART. It cannot be discarded the influence of pre-HIV 
body composition, the cumulative exposure of each drug and the nadir value of CD4 cells, factors that 
could contribute to the risk of lipoatrophy or abdominal prominence that weren’t evaluated. Due to a 
cross-sectional study, it was only able to establish associations and correlations, but not determine 
causality or risk factors between thyroid function and other variables. Finally, the studied sample was 
relatively small, there was homogeneity of age strata compared to other studies (only 15.5% of our 
sample were 60 years or older) and a lack of comparison with a seronegative control group. Therefore, 
further prospective larger studies are needed, starting before cART and with a controlled follow-up, to 
find additional associations and to determine causality between thyroid function and metabolic disorders 
related to cART. 
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CONCLUSION 
 
TSH levels were positively associated with age and negatively with CD4 cell count, even in 
multivariate analysis. Despite of exclusion of patients with thyroid abnormalities from analysis, these 
results raised the interesting possibility that even in the normal range of thyroid function patients can 
have lipid abnormalities and raised blood pressure. So, thyroid function must be considered as a 
continuum spectrum from the euthyroid status to subclinical and overt thyroid dysfunction. 
Our data suggest that thyroid function doesn’t seem to be involved in body fat redistribution 
among HIV-infected patients at least at global serum level, but we do not discard that changes in local 
thyroid hormones availability occur in lipoatrophic or lipohypertrophic areas. However further studies 
are required at this issue. 
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LIST OF ABBREVIATIONS 
AIDS - acquired immune deficiency syndrome; 
BMI - body mass index; 
cART - combined antiretroviral therapy; 
CDC - Centers for Disease Control and Prevention; 
CL - clinical lipodystrophy; 
DIO2 - type 2 iodothyronine deiodinase; 
DXA - dual-energy X-ray absorptiometry; 
FMR - fat mass ratio; 
FT3 - free 3,5,3’-triiodothyronine; 
FT4 - free thyroxine; 
HIV - human immunodeficiency virus; 
IDF - International Diabetes Federation; 
IQR - interquartile range; 
LDL-C - low density lipoprotein cholesterol; 
HDL-C - high-density lipoprotein cholesterol; 
MCT8 - monocarboxylate transporter 8; 
MS - metabolic syndrome; 
NRTI - nucleoside reverse transcriptase inhibitors; 
NNRTI - non-nucleoside reverse transcriptase inhibitors; 
PI - protease inhibitors; 
REE - resting energy expenditure; 
SAT - subcutaneous adipose tissue; 
SD - standard deviation; 
TG - triglycerides; 
TNF-α - tumor necrosis factor alpha; 
TRs - thyroid hormone receptors; 
TSH - thyrotropin.  
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Table 1: Demographic and clinical characteristics according to four groups of body fat distribution. 
 
 No 
lipodystrophy 
Isolated central 
fat accumulation 
Isolated 
lipoatrophy 
Mixed forms of 
lipodystrophy 
P 
N (%) 42 (13.8) 85 (27.9) 95 (31.1) 83 (27.2)  
Demographics      
Gender [n (%)] 
  Male 
  Female 
 
35 (83.3) 
7 (16.7) 
 
40 (47.1) 
45 (52.9) 
 
84 (88.4) 
11 (11.6) 
 
48 (57.8) 
35 (42.2) 
 
 
<0.001 
Age [years, median (IQR)] 40.0 (16.0) 42.0 (18.5) 42.0 (10.0) 51.0 (17.0) <0.001 
Smoking history [n (%)] 
  Never 
  Current 
  Former 
 
13 (31.7) 
24 (58.5) 
4 (9.8) 
 
44 (51.8) 
25 (29.4) 
16 (18.8) 
 
21 (22.8) 
58 (63.0) 
13 (14.1) 
 
41 (50.0) 
21 (25.6) 
20 (24.4) 
 
 
 
<0.001 
Anthropometrics      
Weight [kg, mean (SD)] 64.8 (8.3) 79.0 (14.3) 61.5 (9.6) 71.1 (13.1) <0.001 
Height [m, mean (SD)] 1.67 (0.10) 1.64 (0.09) 1.67 (0.08) 1.64 (0.10) 0.005 
BMI [kg/m2, mean (SD)] 23.0 (2.3) 29.5 (4.6) 21.9 (2.8) 26.5 (3.5) <0.001 
Hip circumference [cm, mean (SD)] 93.8 (4.3) 104.3 (8.5) 88.6 (5.1) 94.5 (6.0) <0.001 
Waist circumference [cm, mean (SD)] 84.1 (6.7) 102.1 (10.9) 83.0 (8.9) 92.4 (12.1) <0.001 
Thigh circumference [cm, mean (SD)] 46.8 (4.1) 52.0 (5.3) 44.8 (3.7) 47.4 (7.8) <0.001 
Neck circumference [cm, mean (SD)] 36.4 (3.4) 37.6 (3.8) 36.1 (3.2) 38.2 (4.2) 0.004 
Arm circumference [cm, mean (SD)] 26.0 (2.9) 29.0 (2.8) 25.5. (2.6) 28.0 (4.8) <0.001 
Waist/hip ratio [mean (SD)] 0.90 (0.08) 0.98 (0.08) 0.94 (0.06) 1.03 (0.07) <0.001 
FMR by DXA [median (IQR)] 0.95 (0.78) 1.17 (0.52) 1.76 (1.36) 1.91 (1.39) <0.001 
Infectious      
HIV-infection [years, median (IQR)]  7.0 (5.0) 6.0 (6.0) 9.0 (5.0) 9.0 (5.0) <0.001 
HIV RNA (<50) [n (%)] 
  Yes 
  No 
 
32 (80.0) 
8 (20.0) 
 
69 (84.1) 
13 (15.9) 
 
86 (90.5) 
9 (9.5) 
 
75 (90.4) 
8 (9.6)) 
 
 
0.235 
CD4 cell count (cells/mm3)      
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  < 200 [n(%)] 
  ≥200 [n(%)] 
5 (11.9) 
37 (88.1) 
4 (4.7) 
81 (95.3) 
8 (8.4) 
87 (91.6) 
7 (8.4) 
76 (91.6) 
 
0.505 
CDC stage [n (%)] 
  A 
  B 
  C 
 
20 (47.6) 
3 (7.1) 
19 (45.2) 
 
50 (58.8) 
1 (1.2) 
34 (40.0) 
 
52 (55.3) 
0 (0.0) 
42 (44.7) 
 
46 (55.4) 
0 (0.0) 
37 (44.6) 
 
 
 
0.129 
cART [years, median (IQR)] 4.0 (6.0) 4.0 (5.0) 8.0 (5.0) 8.0 (5.0) <0.001 
IP [n (%)] 25 (62.5) 51 (62.2) 52 (55.3) 38 (45.8) 0.029 
NNRTI [n (%)] 18 (45.0) 35 (42.7) 47 (50.0) 45 (54.2) 0.169 
NRTI [n (%)] 37 (92.5) 78 (95.1) 93 (98.9) 82 (98.8) 0.118 
HIV risk factor [n (%)] 
  Intravenous drug use 
  Homosexual contact 
  Heterosexual contact 
  Other 
 
15 (35.7) 
5 (11.9) 
22 (52.4) 
0 (0.0) 
 
14 (16.7) 
4 (4.8) 
66 (78.6) 
0 (0.0) 
 
43 (45.7) 
12 (12.8) 
33 (35.1) 
6 (6.4) 
 
10 (12.0) 
11 (13.3) 
59 (71.1) 
3 (3.6) 
 
 
 
 
<0.001 
Cardiovascular Risk Factors      
SBP [mmHg, median (IQR)] 120.0 (20.0) 120.0 (30.0) 110.0 (20.0) 120.0 (20.0) 0.003 
DBP [mmHg, median (IQR)] 80.0 (10.0) 80.0 (10.0) 80.0 (10.0) 80.0 (10.0) 0.733 
Glucose [mg/dL, median (IQR)] 90.0 (23.0) 92.0 (23.0) 93.0 (27.0) 99.0 (39.0) 0.023 
Total cholesterol [mg/dL, median (IQR)] 216.0 (60.0) 235.7 (58.9) 212.6 (56.8) 229.7 (73.0) 0.030 
HDL-C [mg/dL, median (IQR)] 44.9 (12.0) 48.0 (13.8) 43.2 (13.1) 46.5 (11.9) 0.085 
LDL-C [mg/dL, median (IQR)] 130.0 (48.6) 139.7 (48.0) 120.4 (45.3) 137.6 (51.1) 0.032 
TG [mg/dL, median (IQR)] 213.0 (173.0) 178.0 (266.0) 231.0 (250.0) 242.0 (178.0) 0.234 
Leptin [ng/mL, mean (SD)] 3.00 (3.72) 10.25 (9.91) 2.00 (1.78) 4.35 (4.97) <0.001 
Adiponectin [ng/mL, mean (SD)] 4735.5 (5865.6) 1898.0 (2595.0) 2990.0 (7539.2) 4338.4 (3829.5) 0.025 
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Table 2: Thyroid function according to the presence of lipodystrophy (clinically and FMR defined). 
 
 Lipodystrophy  
 Clinical  
 Yes No p 
TSH [mUI/mL, median (IQR)] 1.59 (1.08) 1.44 (1.18) 0.113 
FT3 [pg/mL, median (IQR)] 2.98 (0.71) 2.97 (0.73) 0.792 
FT4 [ng/dL, median (IQR)] 0.94 (0.20) 0.96 (0.20) 0.671 
 FMR  
 Yes No p 
TSH [mUI/mL, median (IQR)] 1.53 (1.13) 1.55 (1.18) 0.437 
FT3 [pg/mL, median (IQR)] 2.98 (0.73) 2.88 (0.76) 0.491 
FT4 [ng/dL, median (IQR)] 0.92 (0.21) 0.92 (0.19) 0.864 
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Table 3: Thyroid function according to the four groups of body fat distribution. 
 
 Lipodystrophy classified by the four groups of body fat distribution  
 No 
lipodystrophy 
Isolated central 
fat accumulation 
Isolated 
lipoatrophy 
Mixed forms of 
lipodystrophy 
p 
TSH [mUI/mL, median (IQR)] 1.40 (1.09) 1.52 (1.50) 1.51 (0.94) 1.71 (1.21) 0.294 
FT3 [pg/mL, median (IQR)] 2.97 (0.76) 2.98 (0.75) 3.07 (0.73) 2.84 (0.67) 0.126 
FT4 [ng/dL, median (IQR)] 0.96 (0.16) 0.94 (0.84) 0.97 (0.24) 0.91 (0.18) 0.223 
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Table 4: Median levels of each parameter of thyroid function according to the presence of metabolic 
syndrome and its individual features. 
 
 TSH [mUI/mL, median (IQR)] FT3 [pg/mL, median (IQR)] FT4 [ng/dL, median (IQR)] 
High blood pressure (mmHg) 
  Absent 
  Present 
P 
 
1.53 (1.21) 
1.53 (1.10) 
0.885 
 
3.05 (0.68) 
2.85 (0.69) 
0.030 
 
0.95 (0.20) 
0.92 (0.19) 
0.389 
High fasting glucose (mg/dL) 
  Absent 
  Present 
P 
 
1.65 (1.36) 
1.51 (1.08) 
0.108 
 
2.97 (0.61) 
3.01 (0.81) 
0.429 
 
0.96 (0.24) 
0.94 (0.19) 
0.154 
Low HDL-C (mg/dL) 
  Absent  
  Present 
P 
 
1.52 (1.20) 
1.60 (1.15) 
0.696 
 
3.00 (0.69) 
2.96 (0.75) 
0.177 
 
0.95 (0.18) 
0.94 (0.21) 
0.669 
High TG (mg/dL) 
  Absent  
  Present 
P 
 
1.49 (1.22) 
1.57 (1.15) 
0.613 
 
2.97 (0.69) 
3.00 (0.74) 
0.788 
 
0.96 (0.19) 
0.94 (0.20) 
0.680 
Waist circumference (cm) 
  Absent  
  Present 
P 
 
1.54 (1.12) 
1.50 (1.20) 
0.942 
 
3.04 (0.76) 
2.93 (0.71) 
0.131 
 
0.96 (0.19) 
0.92 (0.20) 
0.429 
Metabolic syndrome 
  Absent 
  Present 
P 
 
1.52 (1.25) 
1.56 (1.09) 
0.845 
 
3.00 (0.68) 
2.96 (0.80) 
0.270 
 
0.96 (0.21) 
0.92 (0.20) 
0.092 
 
 
  
 
 30 
Table 5: Association between TSH levels and demographic and clinical characteristics. 
 
 β p Adjusted β* p 
TSH (mUI/mL)     
Age (years) 0.006 0.008 0.007 0.005 
Gender -0.020 0.726 0.0004 0.994 
BMI (kg/m2) -0.005 0.391 -0.005 0.408 
CD4  (cells/mm3) -0.108 0.005 -0.107 0.006 
*-The coefficients were adjusted for age, gender and BMI. 
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Table 6: Association between FT3 levels and demographic and clinical characteristics. 
 
 β p Adjusted β* p 
FT3 (pg/mL)     
Age (years) -0.022 0.424 -0.002 0.162 
Gender -0.002 0.001 -0.016 0.572 
BMI (kg/m2) -0.003 0.269 -0.002 0.395 
SBP (mmHg) -0.001 0.074 -0.001 0.325 
DBP (mmHg) -0.001 0.103 -0.001 0.200 
Duration of infection (years) 0.024 0.229 0.020 0.330 
*-The coefficients were adjusted for age, gender and BMI. 
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Table 7: Association between FT4 levels and demographic and clinical characteristics. 
 
 β P Adjusted β* p 
FT4 (ng/dL)     
Age (years) -0.001 0.575 -0.001 0.745 
Gender -0.062 0.096 -0.059 0.122 
BMI (kg/m2) -0.008 0.035 -0.007 0.057 
DBP (mmHg) -0.002 0.158 -0.002 0.258 
Total cholesterol (mg/dL) -0.001 0.018 -0.001 0.064 
LDL-C (mg/dL) -0.001 0.002 -0.001 0.006 
Duration of infection (years) 0.052 0.059 0.047 0.093 
*-The coefficients were adjusted for age, gender and BMI. 
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Language editing 
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Abbreviations 
Abbreviations should be used as sparingly as possible. They should be defined when first used and a list of 
abbreviations can be provided following the main manuscript text. 
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